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Abstract
Today, the technique to directly administer vasodilators
via the airway to treat pulmonary hypertension and to
improve pulmonary gas exchange is widely accepted
among clinicians. The flood of scientific work focussing
on this new therapeutic concept had been initiated by a
fundamental new observation by Pepke-Zaba [1] and
Frostell in 1991 [2]: Both scientists reported, that inhala-
tion of exogenous nitric oxide (NO) gas selectively di-
lates pulmonary vessels without a concomittant sys-
temic vasodilation. No more than another decade ago
NO was identified as an important endogenous vasodila-
tor [3] while having merely been regarded an environ-
mental pollutant before that time. Although inhaled NO
proved to be efficacious, alternatives were sought-after
due to NO’s potential side-effects. In search for the ideal
inhaled vasodilator another group of endogenous me-
diators – the prostanoids – came into the focus of inter-
est. The evidence for safety and efficacy of inhaled pros-
tanoids is – among a lot of other valuable work – based
on a series of experimental and clinical investigations
that have been performed or designed at the Institute for
Surgical Research under the guidance and mentorship of
Prof. Dr. med. Dr. h.c. mult. K. Messmer [4–19]. In the
following, the current and newly emerging clinical appli-
cations of inhaled prostanoids and the experimental data
which they are based on, will be reviewed.
Copyright © 2002 S. Karger AG, Basel
Introduction
The treatment of pulmonary disease by inhaled agents
is an attractive concept. Theoretically, this approach
increases local drug efficacy while minimizing systemic
side-effects. Sympathomimetics, corticosteroids, and an-
tibiotics, among others, have been successfully adminis-
tered via the tracheal route [20]. A decade ago, inhala-
tional therapy has been extended to vasodilatory agents.
The potential benefit of this approach is obvious. Inhaled
vasodilators may cause dilatation of vessels within the
lungs without affecting peripheral vascular tone thereby
avoiding systemic hypotension (‘selective pulmonary va-
sodilation’). It was the unwanted side effects wich made
effective treatment of pulmonary hypertension difficult,
such that until inhalational use of vasodilators was imple-
mented in the 1990’s the disease was regarded untreatable
[21]. Ideally, inhaled vasodilators only reach ventilated
areas of the lung, preserving hypoxic pulmonary vasocon-
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striction in the non-ventilated lung. Increased blood flow
to the ventilated lung improves ventilation-perfusion
matching (VA/Q) and reduces intrapulmonary shunt.
Therefore, inhaled vasodilators may, in addition to selec-
tively dilating pulmonary vessels, increase PaO2 in pa-
tients with hypoxemia due to VA/Q mismatch.
Inhaled Nitric Oxide (iNO)
The first inhaled vasodilator investigated was nitric
oxide (NO), which is gaseous under atmospheric condi-
tions and therefore can be administered via the airway. In
1980, Furchgott and Zawadzki [3] showed that the endo-
thelium is essential for the vasodilator action of acetylcho-
line. Furchgott concluded that acetylcholine stimulated
the endothelial cells to release endothelium-derived relax-
ing factor. Moncada, Palmer and coworkers identified
NO as biologically active form of EDRF [22].
Endogenous NO: Physiologic effects in the pulmonary
vasculature. NO, which is ubiquitarious in the mamma-
lian body, exerts multiple and diverse biological effects,
the most important of which is vasodilation due to
smooth muscle relaxation via the cGMP pathway.
When released from endothelial cells to the pulmonary
vasculature, endogeneously synthezised NO transducts
signals to both, intraluminal and subendothelial effector
cells. It mediates vasodilation of subendothelial smooth
muscle cells. It inhibits fibroblast proliferation and syn-
thesis of growth factors and vasoconstrictors. On the
luminal side it further inhibits aggregation of bypassing
platelets and endothelial adherence of neutrophils. Fur-
ther NO-mediated effects include host defense and neu-
ronal signalling. Among the multifaceted effects of NO
in pulmonary vascular beds the vasodilatory action is
most important for physiological and pathophysiological
processes [22–24].
Inhalation of Exogenous NO
Similar to endogenous NO, iNO causes relaxation of
smooth muscle cells by stimulation of intracellular cGMP
formation. After inhalation, the vasodilatory effect of
iNO is restricted to the lung, because systemically ab-
sorbed, NO is rapidly (within seconds) inactivated by
binding to hemoglobin; iNO does not affect basal pulmo-
nary vascular tone [25–27] but may cause selective pul-
monary vasodilation and improve gas exchange in ani-
mals or humans with pulmonary hypertension and/or
hypoxemia due to VA/Q mismatch [for review see 28–
32]. Species differences exist with respect to the vasodila-
tory potency of iNO [7, 33–35]. Except for one study [36],
tachyphylaxis was not observed during iNO application
[37]. Results from animal studies trying to identify the
exact site of action of NO in the lungs are contradictory
[38, 39]. In patients with adult respiratory distress syn-
drome (ARDS), predominant vasodilation occurred at
pulmonary veins [40]. iNO does not affect cardiac output
[41, 42] and may [43, 44] or may not improve RV func-
tion [5, 45]. Reports on inotropic effects are contradictive
[17, 46]. Of note, NO has been found in exhaled air of
animals [47, 48] and man [49, 50] and autoinhalation of
endogenous NO has been postulated. The number of
scientific publications on the actions and clinical applica-
tions of inhaled nitric oxide (iNO) is abundant and
detailed reviews are available [31, 32, 51–55]. Despite the
recent approval by the FDA and by the EU indicated for
treatment of newborns with hypoxic respiratory failure,
potential side effects of inhaled NO are still a concern.
Potential side effects include direct lung injury [56,
57], inhibition of platelet aggregation [58, 59], and methe-
moglobinemia [30, 60, 61]. Methemoglobin levels of 9.4
and 13.7% have been observed in patients associated with
a deficiency in methemoglobin reductase [62, 63]. Meth-
ylthionine (1 mg/kg) or methylene blue (4 mg/kg) may be
used for treatment [63, 64]. Whether mutagenetic or car-
cinogenic effects of iNO identified in vitro [65, 66] are of
relevance in vivo is still uncertain [67]. Inhaled NO
should be restricted to doses below 10 ppm, since efficacy
has been shown for concentrations in this range [68].
Monitoring of iNO and NO2 concentrations is mandatory
[69, 70]. Furthermore, rebound pulmonary vasoconstric-
tion has been observed after withdrawal of iNO resulting
in hypoxemia [57] and life-threatening pulmonary hyper-
tension [62, 71, 72]. In patients with compromised left
ventricular (LV) function, iNO may result in acute LV
failure and pulmonary edema [73–75], possibly caused by
a deleterious increase of LV preload (due to increased pul-
monary blood flow). There is a recent discussion on a pos-
sible negative inotropic effect of exogenous or endogenous
NO. Endogenous NO has been reported to exert negativ
inotropic effects in vitro [45]. In contrast, own experimen-
tal data do not give evidence for any negative effect of
inhaled NO on myocardial contractility in vivo [17].
Inhaled NO has however been associated with an in-
creased incidence of renal failure in ICU patients [76].
Due to these unwanted side effects of inhaled NO there
have been considerable efforts to identify a vasodilator
void of local and systemic toxicity, that may be inhaled
via the airway and exerts selective pulmonary vasodila-
tion.
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Inhaled Prostacyclin (PGI2)
At present, various prostanoids are under experimen-
tal and clinical investigation for inhalational use. This
review will focus on pharmacology, cardiopulmonary ef-
fects, clinical administration, dosing, and potential side
effects of the various analogues of prostacyclin (PGI2), as
there are epoprostenol (FlolanTM, Glaxo-Wellcome Oper-
ations, Dartford-Kent, UK), iloprost-trometamol (Ilome-
dinTM, Schering, Berlin, Germany), beraprost-sodium
(BeraprostTM, United Therapeutics, Chicago, Ill., USA)
and uniprost (RemodulinTM, United Therapeutics).
Basic Pharmacology and Physiology
Prostacyclin (PGI2) is synthesized in endothelial cells
from arachidonic acid and causes both potent relaxation
of smooth muscle cells and inhibition of platelet aggrega-
tion [77]. These effects are elicited by a receptor-mediated
increase of intracellular cAMP. The human PGI2 receptor
has recently been characterized [78]. Its familiar pharma-
cology, rapid onset of action, short half-life (2–3 min) and
its lack of known toxicity make PGI2 an attractive com-
pound for inhalational therapy [79, 80].
Experimental Data
Selective pulmonary vasodilation upon nebulization
of PGI2 in the experimental setup was first demonstrated
in 1993 by our group in a model of hypoxic pulmonary
vasoconstriction [4, 5] and confirmed by a case report in
3 ARDS patients in the same year [81]. Since then, pul-
monary vasodilation, improved RV function, and/or an
improvement of gas exchange have been reported after
inhalation of PGI2 in various experimental models [82]
including chronic hypoxic pulmonary vasoconstriction
[83]. Similar to iNO, no or not much of a pulmonary
vasodilation has been observed with inhaled PGI2 in pul-
monary hypertension induced by pulmonary microem-
bolism [6] or the thromboxane analogue U46619 [7].
Formerly, the improvement of RV function had been
attributed to a reduction in RV afterload. New data from
our group suggest an intrinsic load-independent positive
inotropic effect of the PGI2 analogues epoprostenol and
iloprost following intravenous administration [18, 19]
and following inhalation, as well [17]. Effects are as-
sumed to be mediated via an increase in cyclic adenosine
monophosphate levels [18]. In combination with inhaled
NO synergistic effects on pulmonary hemodynamics
were observed [84], as well as in combination with phos-
phodiesterase inhibitors [85, 86]. In contrast to inhaled
NO, selectivity of inhaled PGI2 for ventilated lung re-
gions could however not be increased by intravenous
almitrine [87].
Clinical Applications
There have been several initial case reports on the effi-
cacy of inhaled PGI2 in three patients with ARDS, where
a decrease of PAP and intrapulmonary shunt, and an
increase of PaO2 were observed [81], and others (mainly
infants) which displayed either selective pulmonary vaso-
dilation and/or improved gas exchange during inhalation
of PGI2 [88–91]. More recent reports give evidence for the
efficacy of PGI2 in cardiac surgical patients with postop-
erative sepsis [92], with intraoperative right heart failure,
with pneumonia in absence of preexisting lung disease
[93], in children with secondary pulmonary hypertension
due to congenital heart disease [94], and in lung trans-
plant recipients with allograft failure where PGI2 aerosol
was given instead of inhaled NO [95]. If both substances
are combined during the lung transplant procedure, syn-
ergistic effects may be observed [96]. Like reported in
experimental studies, combination of PGI2 with the phos-
phodiesterase inhibitor sildenafil also was associated with
a more pronounced effect than PGI2 alone [97]. Effects of
PGI2 in pneumonia seem to be related to coexisting inter-
stitial lung disease [93]. Effects in ARDS may relate to the
fact, if ARDS is consequence to a primary or secondary
lung damage [98].
Administration and Dosing
PGI2 has to be aerosolized prior to administration.
Both, jet nebulizers [81, 93] and ultrasonic nebulizers [13,
90, 91] have been used for this purpose. Jet nebulizers are
driven by a supplementary gas supply, which must be con-
sidered when setting the respiratory minute volume on
the ventilator. Especially in pressure-controlled ventila-
tion modes which may often be indicated in neonates or
ARDS patients this may require a considerable reduction
of ventilator pressure to maintain inspiratory pressure
unchanged. Sometimes only the standard nebulizing de-
vice of a normal ventilator will be available [99]. Ultra-
sonic nebulizers tend to be bulky and more expensive
than jet nebulizers [100]. However, they showed to deliv-
er aerosols which are assumed to reach the alveolar region
after inhalation [13] even with pressure-controlled mode
and infant ventilator settings. Nebulization time even
may be reduced due to a more effective areosol produc-
tion [101]. This is underlined by the fact that no addition-
al gas flow that would increase inspiratory pressure is
needed to drive the nebulizer. Thus, ultrasound nebuliza-
tion may be assumed the technique of choice for safety
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and efficacy reasons. Dosing of aerosolized drugs is in
principle difficult, because the amount of aerosol actually
reaching alveoli depends on both the underlying patholo-
gy of the lung and the ventilatory setup [100] and may
vary considerably between 0.7% and 15% [100, 102–
104]. A considerable amount of aerosol is trapped in the
ventilator tubing [13]. Administered PGI2 aerosol doses
have to be calculated (1) from the aerosol production rate
per time which has to be measured for any specific combi-
nation of nebulizer and ventilator [13] and (2) from the
concentration of the aerolized PGI2 solution. Adminis-
tered doses range from 2 to 50 ng/kg/min epoprostenol
and from 10 to 300 Ìg iloprost daily. Definite alveolar
deposition only can be verified using fluorescent or ra-
dioactive tracers which is not done at the bedside.
Potential Side Effects
Endogenous PGI2 has no known toxic effect or toxic
metabolites. However, experience with PGI2 as an inhala-
tional agent is limited and few toxicologic data exist.
Potential side effects of PGI2 have been reviewed [80] and
include coughing, facial flushing, headache, and an in-
crease of airway resistance. Most of these effects are tran-
sient and may be negligible in ventilated and sedated
patients. However, preceeding clinical evaluation of PGI2
inhalation in humans, experimental evaluation of side-
effects of prolonged PGI2 administration was indispensi-
ble. Habler and coworkers did not observe cause signs of
acute lung toxicity after prolonged inhalation (8 h) of epo-
prostenol in sheep [9, 10]. Systemic absorption of inhaled
PGI2 may occur at high doses and cause a reversible drop
of blood pressure [81, 93]. Women may be – at identical
doses – more susceptible to systemic hypotension than
men [105]. Bleeding due to inhibition of platelet aggrega-
tion has not been reported. However, there has been
described a platelet aggregation defect following platelet
exposition to low PGI2 concentrations in vitro [106] and
in vivo [107]. Other authors report a mild jaw pain [108].
However, at present at least three uncontrolled long-term
trials have been published, in which iloprost has been
repeatedly administered up to more than one year with-
out obvious adverse effects [109].
Long-Term Effects and Outcome Studies
Such studies have been performed with intravenous
and inhaled analogues of PGI2 predominantly in patients
with pulmonary hypertension. Barst and coworkers [110]
were the first to report improved survival after intrave-
nous epoprostenol as compared to a conventional therapy
for primary pulmonary hypertension in a controlled
study. In contrast, two uncontrolled studies in patients
observed a lack of efficacy of inhaled iloprost. Schenk and
coworkers [111] tried to replace i.v. epoprostenol in 3
patients (NYHA II after 4 years of continuous applica-
tion) by inhaled iloprost. Even though short-term hemo-
dynamic effects were observed, all patients developed
right heart failure and i.v. epoprostenol had to be contin-
ued, which could be done successfully. Machherndl and
coworkers [112] observed neither an improvement of
exercise capacity nor improved pulmonary hemodynam-
ics after an observation period of 10 B 5 months. In con-
trast to the above mentioned results there are – however
also uncontrolled – clinical trials that show positive long-
term effects of oral and inhaled analogues. Olschewski
and coworkers [113] investigated 19 patients with pro-
gressive right heart failure under maximum conventional
therapy. With inhaled iloprost (50–200 Ìg daily), 15 of 19
survived after 3 months, 8 of which improved according
to NHYA class and 7 remained unchanged. In 12 patients
data were available after the 3-month observation time
and showed significant improvement in hemodynamics
and exercise capacity. Similar improvements were re-
ported in patients with pulmonary hypertension second-
ary to pulmonary fibrosis. [113] Hoeper and coworkers
[114] report in 24 patients with primary pulmonary
hypertension improvements in pulmonary hemodynam-
ics and exercise capacity after a daily dose of 100–150 Ìg
inhaled Iloprost over a period of at least one year.
Conclusion
There is convincing evidence that inhaled vasodilators
are effective in selectively dilating pulmonary vessels and
improving gas exchange with low risk of deleterious side-
effects in patients with pulmonary pathology. In this
regard, inhaled vasodilators are clearly superior to sys-
temic vasodilators. NO has been approved for treatment
of newborns with hypoxic respiratory failure. PGI2 might
improve survival and quality of life in primary pulmo-
nary hypertension. A controlled multicenter outcome
study to evaluate the clinical benefit of inhaled PGI2 in
patients with pulmonary hypertension is under way and
preliminary data suggest that patients may significantly
benefit from this treatment. Inhaled prostanoids are an
excellent example, how a therapeutic concept, which orig-
inally was developed and tested in the animal laboratory
setting, may finally reach clinical application and im-
prove patient care.
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